Boule Diagnostics AB Announces Earnings Results for the Quarter Ended June 2021
July 19, 2021 at 03:01 am EDT
Share
Boule Diagnostics AB (publ) announced earnings results for the quarter ended June 2021. For the quarter, the company reported Net sales of SEK 110.7 million compared to SEK 90.6 million, an increase of 22.1%. Operating profit was SEK 2.3 million compared to Operating loss of SEK 3.0 million a year ago. Loss after tax amounted to SEK 1.4 million compared to SEK 43.0 million a year ago. Basic and diluted loss per share amounted to SEK 0.07 compared to SEK 2.21 a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
